B.R.I.S.K. Consulting

Alex Bica, MD, MPH, ExecMSc (Hons), FRSPH

Benefit–risk and drug safety consulting for pharma and biotech

Defensible benefit–risk decisions for pharma and biotech.

Senior scientific advisory in translational safety, clinical development, and decision intelligence.

20+ years bridging nonclinical science, clinical development, and regulatory decision-making.

B.R.I.S.K. Network Visual
THE CHALLENGE

Why Development Programs Stall

The problem is rarely missing data. It’s poorly structured uncertainty.

Safety Assumptions Lost in Translation

Early safety hypotheses are generated but never formally carried into clinical development. Critical assumptions go untested.

Protocols Without Trade-Off Analysis

Clinical protocols are designed without explicit benefit–risk framing. Decisions are made, but the reasoning is not documented.

Governance Without Traceability

Boards and regulators receive conclusions, not the structured reasoning behind them. Decisions lack defensibility.

Data accumulates. Decision clarity does not.

I bring structured reasoning to every stage of drug development — so that decisions are not just made, but made defensibly.

MY APPROACH

What Makes Me Different

Decision-Centric by Design

Every engagement is structured around the decisions you need to make — not around deliverables or reports.

Integrated Across Development

Translational safety, clinical evidence, and governance are treated as a unified architecture, not separate workstreams.

Explicit About Uncertainty

I make assumptions, trade-offs, and probability ranges transparent. No hidden reasoning.

Governance-Ready Outputs

Everything I produce is designed for regulatory, board, and investor scrutiny from day one.

PROCESS

How I Work

A lifecycle approach that ensures decision logic is built in from the start — not retrofitted at the end.

01

Understand

I map your development landscape: safety assumptions, evidence gaps, and the decisions ahead.

02

Structure

I build an explicit decision architecture with documented reasoning, trade-offs, and uncertainty.

03

Defend

I deliver governance-ready outputs that stand up to regulatory, board, and investor scrutiny.

CLIENTS

Who I Work With

Early-Stage Biotech

Approaching first-in-human studies and needing robust safety architecture.

Lean Development Organizations

Teams without dedicated safety physicians who need senior-level strategic oversight.

Programs with Safety Signals

Development programs where emerging signals require expert contextualization and structured responses.

Boards & Investors

Governance bodies requiring independent safety assurance and defensible decision documentation.

Credibility in drug development is built one defensible decision at a time.

Let’s Discuss Your Challenge